Highlights of scientific advancements, major biomanufacturing infrastructure developments, and ecosystem milestones.
This strategic milestone concludes national reliance on sending plasma abroad for fractionation, anchoring the production of critical plasma-derived therapeutics within domestic borders.
Official entry into the elite club of advanced cancer cellular therapy manufacturers in West Asia.
Nationwide coverage of emergency treatment centers for venomous bites, saving thousands of lives in frontier regions.
Elevation of quality control standards, bioassays, and biological batch release certification to the tier of regional reference laboratories.
Entry of six elite health biotechnology startups into formulation R&D and holding venture financing.
Expansion of the national plasma collection network utilizing fully automated plasmapheresis in compliance with WHO standards.
Mastery of technical formulation for advanced oily emulsion adjuvants to boost vaccine immunological efficacy in the livestock and poultry industries.